BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
AstraZeneca (LON: AZN) shares plunged as much as 9% on Wednesday, marking their sharpest one-day decline in years, after the pharmaceutical giant reported disappointing late-stage trial results for its experimental drug Wainua. The setback erased investor optimism surrounding the treatment’s potential in a progressive heart disease and weighed heavily on the FTSE 100 index.
The Phase 3 study found that adding Wainua to the current standard of care failed to significantly reduce the risk of death or major cardiovascular events compared with existing treatment alone. The outcome fell short of market expectations, as many investors had anticipated the drug would achieve its primary endpoint and strengthen AstraZeneca’s cardiovascular pipeline.
The London-listed stock became the biggest drag on the FTSE 100, which slipped about 0.4% in early trading, as investors reassessed the medicine’s commercial outlook.
Morgan Stanley described the trial outcome as a “meaningful downside surprise,” noting that the market had largely expected a successful result despite concerns about the incremental benefit Wainua could offer over established therapies.
The brokerage estimates that consensus forecasts currently include around $3.3 billion in risk-adjusted peak annual sales for Wainua in this heart disease indication. Following the failed trial, analysts expect those revenue projections to be revised significantly lower, which could result in a mid-single-digit percentage reduction in AstraZeneca’s longer-term earnings expectations.
Despite the setback, Morgan Stanley maintained its Overweight rating on AstraZeneca with a 16,500 pence price target. The firm believes investor focus will now shift toward several important late-stage pipeline catalysts expected in the second half of 2026, including lung cancer candidate Dato-DXd, chronic obstructive pulmonary disease treatment tozorakimab, and breast cancer therapy camizestrant.
AstraZeneca and partner Ionis Pharmaceuticals (NASDAQ: IONS) said a full analysis of the Wainua study will be presented at the European Society of Cardiology Congress in August, where additional data may provide further insight into the trial results.
